Leerink Partnrs Has Negative Estimate for RCUS Q3 Earnings

Key Points

• Leerink Partners has significantly downgraded its Q3 2025 earnings estimate for Arcus Biosciences to ($1.34) per share, down from a previous estimate of ($1.09).
• In its recent quarterly report, Arcus Biosciences posted earnings of ($1.11) per share and had a revenue increase of 310.3% year-over-year, totaling $160 million.
• Several financial firms have lowered their price targets for Arcus Biosciences, with Barclays setting a new low target of $14.00, while the overall consensus rating remains a "Moderate Buy".

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Analysts at Leerink Partnrs decreased their Q3 2025 earnings estimates for shares of Arcus Biosciences in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($1.34) per share for the quarter, down from their prior estimate of ($1.09). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences' Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($3.74) EPS, Q1 2026 earnings at ($0.87) EPS, Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($1.00) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($3.82) EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The business had revenue of $160.00 million during the quarter, compared to analyst estimates of $32.86 million. During the same quarter in the previous year, the business earned ($1.02) earnings per share. The company's revenue for the quarter was up 310.3% compared to the same quarter last year.

A number of other brokerages have also issued reports on RCUS. The Goldman Sachs Group lowered their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Barclays lowered their price objective on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research report on Wednesday, April 23rd. Wells Fargo & Company lowered their price target on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday. Finally, Morgan Stanley lowered their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $21.14.

Arcus Biosciences Trading Up 5.8%

RCUS traded up $0.53 during trading hours on Monday, reaching $9.69. 995,373 shares of the company's stock traded hands, compared to its average volume of 1,037,341. The firm has a 50-day moving average price of $9.15 and a 200 day moving average price of $9.38. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.03 billion, a PE ratio of -3.06 and a beta of 0.89.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds have recently made changes to their positions in RCUS. Gilead Sciences Inc. purchased a new stake in shares of Arcus Biosciences during the fourth quarter valued at about $447,610,000. Woodline Partners LP lifted its position in Arcus Biosciences by 45.5% during the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company's stock valued at $40,249,000 after acquiring an additional 1,603,367 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in Arcus Biosciences during the fourth quarter valued at approximately $23,857,000. Vanguard Group Inc. lifted its position in Arcus Biosciences by 24.1% during the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock valued at $52,499,000 after acquiring an additional 1,298,584 shares during the last quarter. Finally, RA Capital Management L.P. purchased a new stake in shares of Arcus Biosciences during the 1st quarter valued at $8,920,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.